Efficient infection and persistence of a herpesvirus saimiri-based gene delivery vector into human tumor xenografts and multicellular spheroid cultures

Cancer Gene Therapy

Volumn 12, Issue 3, 2005, Pages 248-256

  Smith, Peter G ^a,c   Burchill, Sue A ^b   Brooke, David ^b   Coletta, P Louise ^b   Whitehouse, Adrian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Episomal maintenance; Intratumoral injection; Viral vector

Indexed keywords

HERPESVIRUS VECTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; EPISOME; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HERPES VIRUS SAIMIRI; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TRANSGENE; TUMOR XENOGRAFT; VIRUS INFECTION;

ANIMALS; FEMALE; FLUORESCENCE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 2, SAIMIRIINE; HUMANS; MICE; MICE, INBRED BALB C; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPHEROIDS, CELLULAR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

HERPESVIRIDAE; SAIMIRI; SAIMIRIINE HERPESVIRUS 2;

EID: 14644417836     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700788     Document Type: Article

References (37)

1. Albrecht JC, Nicholas J, Biller D, et al. Primary structure of the Herpesvirus saimiri genome. J Virol. 1992;66:5047-5058.
2. Fleckenstein B, Desrosiers RC. Herpesvirus saimiri and herpesvirus ateles. In: Roizman B, ed. The Herpesviruses. Vol 1. New York: Plenum Press; 1982:253-332.
3. Fickenscher H, Fleckenstein B. Herpesvirus saimiri. Philos Trans R Soc. 2001;356:545-567.
4. Duboise SM, Guo J, Czajak S, et al. STP and Tip are essential for herpesvirus saimiri oncogenicity. J Virol. 1998;72:1308-1313.
5. Desrosiers RC, Kamine J, Bakker A, et al. Synthesis of bovine growth hormone in primates by using a herpesvirus vector. Mol Cell Biol. 1985;5:2796-2803.
6. Grassmann R, Fleckenstein B. Selectable recombinant herpesvirus saimiri is capable of persisting in a human cell line. J Virol. 1989;63:1818-1821.
7. Simmer B, Alt M, Buckreus I, et al. Persistence of selectable herpesvirus saimiri in various human haematopoietic and epithelial cell lines. J Gen Virol. 1991;72:1953-1958.
8. Stevenson AJ, Cooper M, Griffiths JC, et al. Assessment of Herpesvirus saimiri as a potential human gene therapy vector. J Med Virol. 1999;57:269-277.
9. Whitehouse A, Stevenson AJ. Gene regulation in Herpesvirus saimiri and its implication towards the development of a novel gene therapy vector. Gene Ther Mol Biol. 1999;3:35-44.
10. Calderwood MA, White RE, Whitehouse A. Development of herpesvirus-based episomally maintained gene delivery vectors. Expert Opin Biol Ther. 2004;4:493-505.
11. Hall KT, Giles MS, Goodwin DJ, et al. Analysis of gene expression in a human cell line stably transduced with Herpesvirus saimiri. J Virol. 2000;74:7331-7337.
12. Smith PG, Coletta PL, Markham AF, et al. In vivo episomal maintenance of a herpesvirus saimiri-based gene delivery vector. Gene Therapy. 2001;8:1762-1769.
13. Stevenson AJ, Clarke D, Meredith DM, et al. Herpesvirus saimiri-based gene therapy vectors maintain heterologous expression throughout mouse embryonic stem cell differentiation in vitro. Gene Therapy. 2000;7:464-471.
14. Frolova-Jones EA, Ensser A, Stevenson AJ, et al. Stable marker gene transfer into human bone marrow stromal cells and their progenitors using novel herpesvirus saimiri-based vectors. J Hematother Stem Cell Res. 2000;9:573-581.
15. Hiller C, Wittmann S, Slavin S, et al. Functional long-term thymidine kinase suicide gene expression in human T cells using a herpesvirus saimiri vector. Gene Therapy. 2000;7:664-674.
16. Hiller C, Tamguney G, Stolte N, et al. Herpesvirus saimiri pathogenicity enhanced by thymidine kinase of herpes simplex virus. Virology. 2000;278:445-455.
17. Knappe A, Feldmann G, Dittmer U, et al. Herpesvirus saimiri-transformed macaque T cells are tolerated and do not cause lymphoma after autologous reinfusion. Blood. 2000;95:3256-3261.
18. Stevenson AJ, Clarke D, Meredith DM, et al. A Herpesvirus saimiri-based gene therapy vector with potential for use in cancer immunotherapy. Cancer Gene Ther. 2000;7:1077-1085.
19. Giles MS, Smith PG, Coletta PL, et al. HVS ORF 73 regulatory region provides long term transgene expression in human carcinoma cell lines. Cancer Gene Ther. 2003;10:49-56.
20. Santini MT, Rainaldi G. Three-dimensional spheroid model in tumour biology. Pathobiology. 1999;67:148-157.
21. Hamilton G. Multicellular spheroids as an in vitro tumour model. Cancer Lett. 1998;131:29-34.
22. Goodwin DJ, Hall KT, Stevenson AJ, et al. The ORF 57 gene product of Herpesvirus saimiri shuttles between the nucleus and cytoplasm and is involved in viral RNA nuclear export. J Virol. 1999;73:10519-10524.
23. Gardella T, Medveczky P, Sairenji T, et al. Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J Virol. 1984;50:248-254.
24. Decker LL, Klaman LD, Thorley-Lawson DA. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol. 1996;70:3286-3289.
25. Decker LL, Babcock GJ, Thorley-Lawson DA. Detection and discrimination of latent and replicative herpesvirus infection at the single cell level in vivo. Methods Mol Biol. 2001;174:111-116.
26. Knappe A, Hiller C, Niphuis H, et al. The interleukin-17 gene of herpesvirus saimiri. J Virol. 1998;72:5797-5801.
27. Calderwood MA, Hall KT, Matthews DA, et al. The Herpesvirus saimiri ORF 73 protein co-localises with host cell mitotic chromosomes and self associates via its C-terminus. J Gen Virol. 2004;85:147-153.
28. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-419.
29. Metheny-Barlow LJ, Li LY. The enigmatic role of angiopoietin-1 in tumour angiogenesis. Cell Res. 2003;13:309-317.
30. Dvorak HF. Leaky tumour vessels: consequences for tumour stroma generation and for solid tumour therapy. Prog Clin Biol Res. 1990;354:317-330.
31. Goodwin DJ, Walters MS, Smith PG, et al. The Herpesvirus saimiri Rta/ORF 50 protein reactivates the lytic replication cycle in a persistently infected A549 cell line. J Virol. 2001;75:4008-4013.
32. Whitehouse A, Cooper M, Meredith DM. The IE gene product encoded by ORF 57 of Herpesvirus saimiri modulates gene expression at a post-transcriptional level. J Virol. 1998;72:857-861.
33. Whitehouse A, Cooper M, Hall KT, et al. The ORF 50a gene product regulates ORF 57 gene expression in Herpesvirus saimiri. J Virol. 1998;72:1967-1973.
34. May WA, Gishizky ML, Lessnick SL, et al. The ES EWS/FLI1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI1. Mol Cell Biol. 1993;13:7393-7398.
35. Kovar H, Aryee DN, Jug G, et al. EWS/FLI1 antagonists induce growth inhibition of Ewing's tumour cells in vitro. Cell Growth Differ. 1996;7:429-437.
36. Kovar H, Ban J, Pospisilova S. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin Cancer Biol. 2003;13:275-281.
37. Prieto J, Herraiz M, Sangro B, et al. The promise of gene therapy in gastrointestinal and liver diseases. Gut. 2003;52:49-54.